BPC-157 for Stomach Ulcers and Gut Health: What the Research Shows

BPC-157 is a synthetic pentadecapeptide that animal studies have linked to faster gastrointestinal tissue repair, including gastric-ulcer and esophageal models. Research protocols commonly cite 250–500 mcg once or twice daily for 4–12 weeks. Human evidence is limited and BPC-157 is not FDA-approved. This guide covers mechanism, gut-specific findings, dosing parameters, safety, and 2026 legal status.

BPC-157 and gut health at a glance

• Class: synthetic pentadecapeptide (research peptide), derived from a protein found in human gastric juice
• Commonly cited dose: 250–500 mcg per injection (oral capsule forms are also marketed)
• Frequency: once or twice daily
• Typical research cycle: 4–12 weeks
• Best-studied gut uses (animal models): gastric ulcer, esophagitis, intestinal anastomosis, colitis, fistula healing
• Human evidence: one published Phase I safety/PK study and an unpublished Phase II ulcerative-colitis program (PL 14736)
• FDA status (June 2026): not approved; under Pharmacy Compounding Advisory Committee (PCAC) review for the 503A bulks list on July 23, 2026

What is BPC-157 and why is it studied for the gut?

BPC-157 stands for "Body Protection Compound-157," a stable synthetic peptide made of 15 amino acids. It is a partial sequence derived from a protein originally isolated from human gastric juice, which is one reason researchers have focused so heavily on its effects in the digestive tract.

A defining property is its stability in the stomach. BPC-157 is described as essentially stable and native in human gastric juice, meaning it is not immediately broken down by stomach acid the way many peptides are (Sikiric et al., 2020, Gut Liver). That stability is the basis for interest in oral and intragastric delivery for gastrointestinal conditions.

It is important to be precise about the evidence base. The overwhelming majority of BPC-157 gut research comes from rodent models, conducted largely by a single research group at the University of Zagreb. Replication by independent laboratories and large human trials are still lacking.

How does BPC-157 work in the digestive tract?

The most consistently reported mechanism is promotion of angiogenesis — the growth of new blood vessels into injured tissue. In animal models, BPC-157 has been associated with upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and activation of the downstream Akt–eNOS pathway, increasing blood-vessel density at the wound bed (Sikiric et al., 2020, Gut Liver).

A second proposed mechanism is modulation of the nitric oxide (NO) system. Rather than acting in one direction, BPC-157 appears to counteract both NO-synthase blockade and NO-synthase overstimulation in animal experiments, which the authors describe as a homeostatic, stabilizing effect on the gut and vasculature (Sikiric et al., 2020, Gut Liver).

For the digestive lining specifically, researchers frame these effects within the concept of "cytoprotection" — protecting and helping rebuild mucosal cells. In animal studies, BPC-157 has been reported to accelerate rebuilding of glandular epithelium and formation of granulation tissue in chronic gastric-ulcer models (Xue et al., 2004, World J Gastroenterol).

Read our BPC-157 complete guide for a deeper look at the full mechanism beyond the gut.

What does research show about BPC-157 and stomach ulcers?

The clearest gut finding comes from a controlled rat study. Both intramuscular and intragastric BPC-157 reduced gastric-ulcer area, with intramuscular delivery proving more effective; ulcer-inhibition rates ranged from roughly 45.7% to 65.6%, and the higher-dose intramuscular groups outperformed the comparison drug famotidine in that experiment (Xue et al., 2004, World J Gastroenterol).

Beyond the stomach itself, BPC-157 has been studied across several other gut-injury models in rats:

• Esophagitis and sphincter failure: BPC-157 was reported to recover esophagitis and restore pressure in both esophageal sphincters in a prolonged-esophagitis rat model, whereas ranitidine showed no therapeutic effect in the same experiment (Petrovic et al., 2006, J Pharmacol Sci).
• Fistula and anastomosis healing: BPC-157 accelerated closure of colocutaneous fistulas in rats, an effect the authors linked to the nitric oxide system (Klicek et al., 2008, J Pharmacol Sci).

These are preclinical results. "Research in animal models suggests BPC-157 may support gastrointestinal tissue repair" is an accurate reading of the literature; "BPC-157 heals stomach ulcers in humans" is not. The famotidine comparison above describes a rodent experiment, not a human head-to-head trial. Consult your healthcare provider before considering any peptide for a gastrointestinal concern.

Is there any human evidence for BPC-157 and gut health?

Limited human data exist, and they sit at the early-trial stage. BPC-157 was advanced into clinical development under the drug code PL 14736 (also called PL-10 / PLD-116) by the Croatian company Pliva as a candidate for ulcerative colitis.

A first-in-human study reported that rectally administered PL 14736 was safe and well tolerated in healthy male volunteers, supporting progression to a patient trial (Veljaca et al., 2003, Gut — conference abstract). A subsequent randomized, double-blind, placebo-controlled Phase II study in mild-to-moderate ulcerative colitis was initiated, but its full results were never published in a peer-reviewed clinical journal [VERIFY: Phase II ulcerative-colitis efficacy outcome — no published primary trial report located]. That publication gap is a meaningful limitation: efficacy claims for human IBD cannot be independently verified.

In short, the human safety signal to date is reassuring at the doses tested, but human efficacy for stomach ulcers, "leaky gut," or IBD remains unproven. Consult your healthcare provider before starting any peptide protocol.

What dosing parameters appear in BPC-157 gut research?

Dosing below describes parameters reported in research and commonly cited by clinicians who compound peptides — it is not a recommendation to self-administer.

For suspected gastrointestinal issues, some protocols favor oral delivery on the rationale that BPC-157 is stable in gastric juice and may act locally on the gut lining (Sikiric et al., 2020, Gut Liver). Human dosing has not been established by regulators, and animal-to-human dose translation is not validated.

Dosing should be personalized with a qualified provider, never copied from a forum. Our BPC-157 dosage guide covers reconstitution and unit-conversion concepts at a high level. Consult your healthcare provider before starting any peptide protocol.

What are the side effects and safety considerations?

Human safety data are thin but, where they exist, encouraging at low doses. In the first-in-human PL 14736 study, rectal administration was reported as safe and well tolerated in healthy volunteers (Veljaca et al., 2003, Gut). Toxicology summaries from the originating group report no adverse effects and that a lethal dose (LD1) was not reached in animal testing (Sikiric et al., 2020, Gut Liver).

That said, key safety gaps remain, and you should weigh them with a clinician:

• Angiogenesis and cancer uncertainty. BPC-157 promotes blood-vessel growth. Because tumors also depend on angiogenesis, long-term safety in people with a personal or family cancer history is unknown and warrants caution.
• No long-term human data. There are no large, long-duration human trials, so chronic-use risks are uncharacterized.
• Product-quality risk. Research-only and gray-market BPC-157 is not subject to drug-grade manufacturing oversight; contamination, mislabeling, and inaccurate dosing are documented risks across the unregulated peptide market.
• Interactions. BPC-157 has not been formally studied for drug interactions; if you take medications affecting the gut, clotting, or blood vessels, review them with a provider. See our peptide interaction checker.

Consult your healthcare provider before starting any peptide protocol, especially if you have an active cancer diagnosis, are pregnant or breastfeeding, or take prescription medication.

Is BPC-157 legal? FDA and sourcing status in 2026

BPC-157 is not FDA-approved for any condition, and the regulatory picture is actively shifting in 2026.

In 2023, the FDA placed BPC-157 in Category 2 of its interim 503A bulk-substances list — substances flagged for significant safety questions and effectively barred from compounding (FDA / Federal Register docket). In April 2026, the FDA published a notice reorganizing peptide bulk substances and scheduling a Pharmacy Compounding Advisory Committee (PCAC) review (FDA, Federal Register notice 2026-07361, April 16, 2026).

At that PCAC meeting on July 23–24, 2026, BPC-157 (free base) and BPC-157 acetate are among the bulk drug substances being considered for inclusion on the Section 503A bulks list, alongside KPV, TB-500, and MOTS-c (FDA Advisory Committee Calendar, July 23–24, 2026). Removal from a prohibited category is not the same as approval, and no outcome is guaranteed; the committee's recommendation will shape whether compounding pharmacies can legally prepare BPC-157 going forward.

Until the 503A status resolves, BPC-157 sold online is typically labeled "for research use only," which is not authorized for human use. Legal status varies by jurisdiction; consult a lawyer for binding advice. Track changes on our BPC-157 legal status page.

Frequently asked questions

Q: Can BPC-157 heal a stomach ulcer? A: In rat studies, BPC-157 reduced gastric-ulcer area and accelerated mucosal rebuilding, with ulcer-inhibition rates around 45–66% in one controlled experiment (Xue et al., 2004, World J Gastroenterol). However, these are animal results — there are no published human trials showing BPC-157 heals stomach ulcers in people. Research in animal models suggests it may support gastric tissue repair, but that is not the same as a proven human treatment. If you have ulcer symptoms, see a healthcare provider for evaluation and evidence-based care.

Q: Is BPC-157 better taken orally for gut issues? A: Researchers focus on oral and intragastric BPC-157 for gut conditions because the peptide is reported to be stable in human gastric juice, meaning stomach acid does not immediately destroy it (Sikiric et al., 2020, Gut Liver). The rationale is that an orally delivered dose may act locally on the digestive lining. That said, optimal route and dose in humans have not been established by regulators. Discuss delivery options with a provider rather than assuming one route is superior.

Q: Does BPC-157 help with leaky gut or IBD? A: Animal models of colitis and intestinal injury show BPC-157 may support mucosal healing, and it reached early human trials for ulcerative colitis as PL 14736 (Klicek et al., 2008, J Pharmacol Sci). But the human Phase II efficacy results were never published, so claims about "leaky gut" or inflammatory bowel disease in people remain unproven. Use caution with marketing that presents these as established uses, and consult your healthcare provider.

Q: How long does BPC-157 take to work for gut healing? A: Animal studies and anecdotal reports often describe digestive effects within a few weeks, and research cycles commonly run 4–12 weeks. Because controlled human gut-healing trials have not been published, there is no validated human timeline. Individual response varies, and "feeling better" is not a substitute for confirmed mucosal healing on testing. Discuss realistic expectations and monitoring with a healthcare provider.

Q: Is BPC-157 safe for the stomach and gut? A: Early human data — chiefly the PL 14736 study, in which rectal dosing was well tolerated in volunteers — are reassuring at low doses, and animal toxicology reported no adverse effects (Veljaca et al., 2003, Gut; Sikiric et al., 2020, Gut Liver). But there are no long-term human safety studies, and BPC-157's angiogenic activity raises unresolved questions for anyone with a cancer history. Product quality on the gray market is also a real risk. Consult your healthcare provider before use.

Q: Is BPC-157 legal to buy in the US in 2026? A: BPC-157 is not FDA-approved. It was placed in Category 2 of the interim 503A bulks list in 2023, and on July 23–24, 2026, a Pharmacy Compounding Advisory Committee is reviewing whether BPC-157 should be added to the 503A bulks list for compounding (FDA Advisory Committee Calendar, July 23–24, 2026). Products sold online are usually "research use only," which is not authorized for human use. Legal status varies by jurisdiction; consult a lawyer for binding advice.

References

1. Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032–1036. PMID: 15052688
2. Petrovic I, Dobric I, Drvis P, et al. An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157. J Pharmacol Sci. 2006;102(3):269–277. PMID: 17116974
3. Sikiric P, Rucman R, Turkovic B, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153–167. doi:10.5009/gnl18490 · PMC7096228
4. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci. 2008;108(1):7–17. Full text (J-Stage)
5. Veljaca M, Pavic Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut. 2003;52(Suppl VI):A57 (abstract). Record
6. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. FDA.gov
7. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments — Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List. Federal Register, April 16, 2026 (Docket No. 2026-07361). federalregister.gov